Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. scores highest on Anchor (52) and lowest on Price (20). Its PosiPenta is 34.22 out of 100, weaker than most similar companies.
On the Penta Grid this week, Mineralys Therapeutics, Inc. is Grid #692 of 837 in the Healthcare sector in United States, and Grid #3,354 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | 34.22 | 20 | 34 | 26 | 39 | 52 |
| DENTSPLY SIRONA Inc. | 43.90 | 36 | 57 | 42 | 35 | 49 |
| Establishment Labs Holdings Inc. | 38.04 | 1 | 62 | 58 | 10 | 59 |
| BioLife Solutions Inc | 58.21 | 30 | 47 | 97 | 74 | 44 |
| ADARx Pharmaceuticals, Inc. | 46.78 | 0 | 46 | 61 | 56 | 71 |
| Septerna, Inc. | 47.77 | 15 | 32 | 75 | 65 | 52 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.81 |
| P/B ratio | 3.26 |
EEarnings
| Trailing EPS | ₹-399.70 |
| Forward EPS | ₹-232.68 |
NNitro
| Price | 1922.71 |
| 52-week high | 4513.17 |
| 52-week low | 1905.66 |
| Fall from 52-week high | 57.4% |
TTorque
| Return on equity (ROE) | -80.88% |
| Debt-to-equity | 0.18 |
AAnchor
| Beta (price swings) | 0.69 |
| Market cap | ₹16,998 Cr |
| Insider holding | 0.70% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Mineralys Therapeutics, Inc.'s PosiPenta score?
Mineralys Therapeutics, Inc.'s PosiPenta is 34.22 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Mineralys Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Mineralys Therapeutics, Inc. is Grid #692 of 837 in the Healthcare sector in United States, and Grid #3,354 of 4,000 in United States.
Which PosiPenta pillar is strongest for Mineralys Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 52 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Mineralys Therapeutics, Inc.?
Price (valuation), with a score of 20 out of 100: weaker than most similar companies.
Has Mineralys Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.56 points, from 31.66 to 34.22.
PositoAI is for research and education only and is not investment advice.